Crescendo Bioscience, a US-based developer of quantitative blood tests for rheumatoid arthritis in which strategic investor Myriad Genetics has a three-year option to buy the company, has raised $28m in its series D round.
Venture capital firms Skyline Ventures and Safeguard Scientifics co-led the round, and were joined by peers Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers and Aeris Capital, the investment office of Germany-based software maker SAP’s co-founder Klaus Tschira, .
Ferghana Partners served as placement agent.
In September 2011, Crescendo raised $31m in its C round with a further $25m in venture debt and buyout option provided by strategic investor Myriad Genetics.
Crescendo previously raised $5m in its B round in late 2009 to take its then-total since launch to $20m.